![Christopher Mark Edwards](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Mark Edwards
Secrétaire Général chez Wright & Offland Holdings Ltd.
Profil
Christopher Mark Edwards is the founder of Pulmagen Therapeutics (Synergy) Ltd., which was founded in 2000.
He is currently working as a Secretary at Wright & Offland Holdings Ltd.
Postes actifs de Christopher Mark Edwards
Sociétés | Poste | Début |
---|---|---|
Wright & Offland Holdings Ltd.
![]() Wright & Offland Holdings Ltd. Home FurnishingsConsumer Durables Wright & Offland Holdings Ltd. manufactures and wholesales glass and glass products. The company was established in 1988 and is headquartered in Manchester, GB | Secrétaire Général | 01/06/2006 |
Anciens postes connus de Christopher Mark Edwards
Sociétés | Poste | Fin |
---|---|---|
Pulmagen Therapeutics (Synergy) Ltd.
![]() Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Fondateur | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Wright & Offland Holdings Ltd.
![]() Wright & Offland Holdings Ltd. Home FurnishingsConsumer Durables Wright & Offland Holdings Ltd. manufactures and wholesales glass and glass products. The company was established in 1988 and is headquartered in Manchester, GB | Consumer Durables |
Pulmagen Therapeutics (Synergy) Ltd.
![]() Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |